Two med-tech companies agreed to settlements with the U.S. government to resolve False Claims Act (FCA) allegations that they submitted Medicare claims for medically unnecessary testing and devices.
New research has teased out specific aspects of how Epstein-Barr virus (EBV) sparks the immune response that leads on to the development of multiple sclerosis (MS), opening the way to the rational design of vaccines and antivirals that address the root cause of the disease.
New research has teased out specific aspects of how Epstein-Barr virus (EBV) sparks the immune response that leads on to the development of multiple sclerosis (MS), opening the way to the rational design of vaccines and antivirals that address the root cause of the disease.
Astrazeneca plc has added a dual PDE3/4 inhibitor candidate to its chronic obstructive pulmonary disease (COPD) portfolio via a deal worth up to $2.1 billion with Chia Tai Tianqing Pharmaceutical Group Co. Ltd., a Sino Biopharmaceutical Ltd. subsidiary.
Cancer researchers are increasingly turning to the microbiome to understand why some patients respond well to treatment while others face severe complications. Gut microbial communities shift during intensive therapies such as bone marrow transplantation, and those changes influence infection risk, immune recovery and long‑term survival. New advances in microbial sequencing and engineering redefine this community as a measurable clinical parameter that can be monitored, modeled, and even therapeutically reshaped to improve outcomes in oncology and other conditions.
Shanghai Peptidstar Therapeutics Ltd. has divulged new cyclic peptides acting as interleukin-23 receptor (IL-23R) antagonists potentially useful for the treatment of psoriasis, arthritis and inflammatory bowel disease.
Thioredoxin reductase 1 (TXNRD1) is a key component of the thioredoxin antioxidant system that helps maintain cellular redox homeostasis and regulates critical cellular processes such as proliferation, apoptosis and immune responses. A team of researchers at Central South University systematically investigated TXNRD1 expression and function in psoriatic keratinocytes using gene expression datasets, clinical samples and in vitro and in vivo models.
While the emergence of immune checkpoint inhibitor (ICI) therapy in recent years has significantly improved cancer outcomes, some patients have been unable to experience the full therapeutic benefits of ICIs due to significant gastrointestinal inflammation linked to treatment. Seres Therapeutics Inc. is looking to change that with its live biotherapeutic candidate, SER-155, offering impressive findings from phase I data in ICI-related enterocolitis, or irEC.
Astrazeneca plc has added a dual PDE3/4 inhibitor candidate to its chronic obstructive pulmonary disease (COPD) portfolio via a deal worth up to $2.1 billion with Chia Tai Tianqing Pharmaceutical Group Co. Ltd., a Sino Biopharmaceutical Ltd. subsidiary.
Cancer researchers are increasingly turning to the microbiome to understand why some patients respond well to treatment while others face severe complications. Gut microbial communities shift during intensive therapies such as bone marrow transplantation, and those changes influence infection risk, immune recovery and long‑term survival. New advances in microbial sequencing and engineering redefine this community as a measurable clinical parameter that can be monitored, modeled, and even therapeutically reshaped to improve outcomes in oncology and other conditions.
RSS
